Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes QTLs Strains Markers Genome Information Ontologies Cell Lines References FTP Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) RatMine GViewer (Genome Viewer) Overgo Probe Designer ACP Haplotyper Genome Scanner
Aging & Age-Related Disease Cancer Cardiovascular Disease COVID-19 Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models PhenoMiner (Quantitative Phenotypes) Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes GERRC (Gene Editing Rat Resource Center) Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Poster Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:artemether
go back to main search page
Accession:CHEBI:195280 term browser browse the term
Definition:An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.
Synonyms:exact_synonym: (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine
 related_synonym: (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane;   10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane;   Formula=C16H26O5;   InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1;   InChIKey=SXYIRMFQILZOAM-HVNFFKDJSA-N;   SMILES=[H][C@@]12CC[C@@]3(C)OO[C@@]11[C@@]([H])(CC[C@H]2C)[C@@H](C)[C@@H](OC)O[C@]1([H])O3;   artemetero;   artemetherum;   artemisininelactol methyl ether;   beta-artemether;   beta-dihydroartemisinin methyl ether;   dihydroartemisinin methyl ether;   methyl-dihydroartemisinine
 xref: Beilstein:6569878;   CAS:71963-77-4;   DrugBank:DB06697;   Drug_Central:245;   KEGG:D02483;   LINCS:LSM-5519
 xref_mesh: MESH:C032942
 xref: PMID:11141088;   PMID:12781185;   PMID:16033274;   PMID:17242150;   PMID:17404003;   PMID:18243702;   PMID:3279208;   Wikipedia:Artemether

show annotations for term's descendants           Sort by:
 
artemether term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 multiple interactions ISO [Artemether co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA CTD PMID:31312845 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 affects expression
multiple interactions		 ISO artemether affects the expression of NR1I3 mRNA alternative form
[Artemether co-treated with NR1I3 protein alternative form] results in increased expression of CYP2B6 mRNA; Artemether binds to and results in increased activity of NR1I3 protein alternative form		 CTD PMID:24721719, PMID:31312845 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277 		JBrowse link
Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19785
    chemical entity 19785
      group 19696
        inorganic group 19146
          peroxy group 3218
            peroxides 3218
              organic peroxide 100
                artemether 2
Path 2
Term Annotations click to browse term
  CHEBI ontology 19785
    subatomic particle 19782
      composite particle 19782
        hadron 19782
          baryon 19782
            nucleon 19782
              atomic nucleus 19782
                atom 19782
                  main group element atom 19670
                    p-block element atom 19670
                      carbon group element atom 19572
                        carbon atom 19561
                          organic molecular entity 19561
                            organic group 18493
                              organic divalent group 18486
                                organodiyl group 18486
                                  carbonyl group 18389
                                    carbonyl compound 18389
                                      carboxylic ester 14073
                                        lactone 5978
                                          terpene lactone 1770
                                            sesquiterpene lactone 1619
                                              (+)-artemisinin 94
                                                artemisinin derivative 73
                                                  artemether 2
paths to the root

Contact Us |  About Us |  License CC BY 4.0 |  Legal Disclaimer |  © Medical College of Wisconsin
NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.